Evidence map›Paper›PMID 25964225›Full record

SynthesisThe American journal of gastroenterology2015

C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Mahmoud H Mosli, Guangyong Zou, Sushil K Garg, Sean G Feagan, John K MacDonald, Nilesh Chande, William J Sandborn, Brian G Feagan

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 330 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
330citing papers in PubMed, 9 pooled it
31.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03808506 withdrawnnot on this mapstarted 2019, after this paper: background citation

Relationship Between Baseline Burden of Disease and Anti-TNF Drug Trough Levels in Ulcerative Colitis.

TypeobservationalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2019 to 2022Enrolled0ConditionsUlcerative ColitisArmsFecal calprotectin
NCT04491799 completednot on this mapstarted 2019, after this paper: background citation

Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea

TypeobservationalSponsorMahidol UniversityRan2019 to 2020Enrolled135ConditionsDiarrhea, CalprotectinArmsFecal calprotectin
3 · Its place in the literature

Who cites it

330 citing papers in PubMed, 9 syntheses or guidelines pooled it, 662 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Terminal Ileitis on Imaging Is Rarely Crohn's Disease: A 10-Year Retrospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Article

270 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Mahmoud H Mosli1] Department of Medicine, University of Western Ontario, London, Ontario, Canada [2] Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia [3] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada.
Guangyong Zou1] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada [2] Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
Sushil K GargDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Sean G FeaganRobarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada.
John K MacDonaldRobarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada.
Nilesh Chande1] Department of Medicine, University of Western Ontario, London, Ontario, Canada [2] London Health Sciences Centre, Victoria Hospital, London, Ontario, Canada.
William J Sandborn1] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada [2] Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Brian G Feagan1] Department of Medicine, University of Western Ontario, London, Ontario, Canada [2] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada [3] Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
Robarts Clinical Trials · CAUniversity of Minnesota · USWestern University · CA

Funding

Canadian Institutes of Health Research 105529
6 · The paper itself

Abstract

objectivesPersistent disease activity is associated with a poor prognosis in inflammatory bowel disease (IBD). Therefore, monitoring of patients with intent to suppress subclinical inflammation has emerged as a treatment concept. As endoscopic monitoring is invasive and resource intensive, identification of valid markers of disease activity is a priority. The objective was to evaluate the diagnostic accuracy of C-reactive protein (CRP), fecal calprotectin (FC), and stool lactoferrin (SL) for assessment of endoscopically defined disease activity in IBD.

methodsDatabases were searched from inception to November 6, 2014 for relevant cohort and case-control studies that evaluated the diagnostic accuracy of CRP, FC, or SL and used endoscopy as a gold standard in patients with symptoms consistent with active IBD. Sensitivities and specificities were pooled to generate operating property estimates for each test using a bivariate diagnostic meta-analysis.

resultsNineteen studies (n=2499 patients) were eligible. The pooled sensitivity and specificity estimates for CRP, FC, and SL were 0.49 (95% confidence interval (CI) 0.34-0.64) and 0.92 (95% CI 0.72-0.96), 0.88 (95% CI 0.84-0.90) and 0.73 (95% CI 0.66-0.79), and 0.82 (95% CI 0.73-0.88) and 0.79 (95% CI 0.62-0.89), respectively. FC was more sensitive than CRP in both diseases and was more sensitive in ulcerative colitis than Crohn's disease.

conclusionsAlthough CRP, FC, and SL are useful biomarkers, their value in managing individual patients must be considered in specific clinical contexts.

Indexed as

BiomarkersColitis, UlcerativeC-Reactive ProteinCrohn DiseaseEndoscopy, GastrointestinalFecesHumansLactoferrinLeukocyte L1 Antigen ComplexSensitivity and SpecificityBiomarkersC-Reactive ProteinLactoferrinLeukocyte L1 Antigen Complex

Identifiers

PMID25964225
OpenAlexW2105857910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.